Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06444841Recruiting
Memory aids for mild memory loss
This study tests whether using a paper-based or smartphone-based memory support system helps people with mild memory problems remember daily tasks. You and a family member or friend will both participate.
Austin, TexasAges 50 years+ - NCT06493292Recruiting
Treating a blocked dialysis fistula with balloon therapy
This trial tests a balloon treatment for blocked blood vessels in the arm used for dialysis. It aims to improve blood flow so dialysis can work better.
Zhengzhou, HenanAges 18–75 - NCT07811687Recruiting
Liver and spleen surgery for liver cancer with cirrhosis
This study tests whether removing part of the liver along with the spleen during laparoscopic (keyhole) surgery helps improve liver function and the immune system in people with liver cancer and cirrhosis. If you qualify, you may have better surgical outcomes and recovery.
Yangzhou, JiangsuAges 18–80 - NCT07813208Recruiting
Treatment and survival of children with ph+ acute lymphoblastic leukemia
This study looks back at the diagnosis, treatment, and survival of children with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to understand how well standard treatments, including targeted therapy, work in these patients.
Hangzhou, ZhejiangAges 1 month–18 years - NCT07811765Recruiting
Iron treatment before vs during early pregnancy
This study compares starting iron supplements before pregnancy versus waiting until the first trimester (first 3 months) to treat iron deficiency anemia. It aims to see which timing better improves health for mothers and babies.
Zhaotong, YunnanAges 18–45 - NCT07816601Recruiting
Donor breast milk for premature babies in the NICU
This study looks at whether giving donor breast milk to premature babies born between 29 and 32 weeks helps them feed better and grow. If your baby is in the NICU and eligible, they may receive donor breast milk for most of their feedings.
Orlando, FloridaAges 7 months–8 months - NCT07813390Enrolling by invitationPhase 2
New drug combo for leukemia that is no longer responding to venetoclax
This trial tests a combination of three drugs—homoharringtonine, lisaftoclax, and azacitidine—for people with acute myeloid leukemia (AML) whose cancer did not respond to or has returned after prior treatment with venetoclax. The goal is to see if this new combination can help control the leukemia when current options have failed.
Guangzhou, GuangdongAges 18 years+ - NCT06301425Recruiting
Transplant study for high-risk AML based on MRD response
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
BeijingAges 16–65 - NCT06376786Recruiting
Italian iTTP Registry for acute episodes
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
Milan, MIAges 12–99 - NCT06496308RecruitingPhase 3
Adding orelabrutinib to standard therapy for mantle cell lymphoma
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
ShanghaiAges 18–80 - NCT06494371RecruitingPhase 1
Study of LCAR-HL30 for Hodgkin's and anaplastic large cell lymphoma
This trial tests a new treatment called LCAR-HL30 for people with Hodgkin's lymphoma or anaplastic large cell lymphoma that has come back or not responded to therapy. The treatment targets cells with a protein called CD30 to help your body fight the cancer.
ShanghaiAges 18–75 - NCT06244264Recruiting
Using your own blood during spine surgery for lung cancer
This study tests the safety and effectiveness of using your own blood (collected before surgery) during spine surgery for lung cancer that has spread to the backbone. It may help people whose spine is unstable or causing nerve problems.
Guangzhou, GuangdongAges 18–75 - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT06197204Recruiting
Finding biomarkers in Langerhans cell histiocytosis
This study is looking for adults with Langerhans cell histiocytosis (LCH) and also for adults with certain lung conditions (like cystic lung disease or emphysema) or healthy smokers to act as controls. The goal is to find biomarkers (signs in the body) that can help doctors diagnose LCH, predict how it will progress, and see how well treatment is working.
ParisAges 18 years+ - NCT07802405RecruitingPhase 1
Testing a new drug alone or with ruxolitinib for myelofibrosis
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
Zhengzhou, HenanAges 3 weeks+ - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75 - NCT07808931Recruiting
Long flight after cosmetic surgery: effect of seat class and compression stockings on leg vein swelling
This study looks at how different seating classes (business/first vs. economy) and wearing compression stockings on long flights affect leg vein swelling after cosmetic surgery. Participants will have an ultrasound to check the veins before and after the flight.
BogotáAges 18–65 - NCT07808411Recruiting
Leg vein size changes in the first two days after long flights to Bogota
This study measures the size of a vein in your leg before, during, and after a long flight to Bogota. It aims to understand how flying affects that vein, which may help prevent blood clots. You must be flying to Bogota for at least 4 hours and be willing to have several vein ultrasounds.
BogotáAges 18–65 - NCT07802717RecruitingPhase 1
CAR T cell therapy for returning multiple myeloma
This trial tests a new treatment called VV169, a type of CAR T cell therapy, for people with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if it is safe and if it can help fight the cancer.
Rochester, MinnesotaAges 18 years+ - NCT06505369RecruitingPhase 2
Immune therapy for newly diagnosed multiple myeloma before stem cell transplant
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
CopenhagenAges 18–70 - NCT07805096Recruiting
Smart health app for children with cancer and their parents
This study tests a smart health app designed to support the mental, physical, and spiritual well-being of children with leukemia or a brain tumor and their parents. It aims to see if the app helps improve overall health and quality of life.
TaipeiAges 7 years+ - NCT07808827RecruitingPhase 3
New targeted drug plus chemo for large b-cell lymphoma
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07805083Recruiting
Improving consent understanding with a video tool
This study is testing a new way to explain clinical trial information to people using a video or online tool, to see if it helps them understand better. You may be able to join if you are an English-speaking adult living in the U.S.
Jacksonville, FloridaAges 18 years+ - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.